• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    52.80 -5.98 (-10.17%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CRISPR Therapeutics AG - Common Shares

    < Previous 1 2
    ...
    6 7 8 9 10 11 12 13 14
    ...
    35 36 Next >
    News headline image
    3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000 ↗
    Each of these three companies are entering a new era of growth. 
    Via The Motley Fool
    News headline image
    Buying These Dirt-Cheap Stocks Could Be a Brilliant Move ↗
    The price could be right for these three biopharma stocks. 
    Via The Motley Fool
    News headline image
    3 Stocks That Could Be the Next Big Thing in Gene Editing ↗
    Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
    Via InvestorPlace
    News headline image
    Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
    Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
    Via MarketBeat
    News headline image
    If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today ↗
     
    Via Benzinga
    News headline image
    Is It Too Late to Buy CRISPR Therapeutics Stock? ↗
    The biotech has been making a lot of noise since late last year. 
    Via The Motley Fool
    News headline image
    If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today ↗
     
    Via Benzinga
    News headline image
    Smart Money Is Betting Big In CRSP Options ↗
     
    Via Benzinga
    News headline image
    The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024 ↗
    These undervalued Cathie Wood stocks capture her favorite trends and remain undervalued even as the wider tech sector surge. 
    Via InvestorPlace
    News headline image
    7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗
    With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
    Via InvestorPlace
    News headline image
    Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz ↗
    On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new 
    Via Benzinga
    News headline image
    It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility ↗
    Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
    Via Talk Markets
    News headline image
    The Top 3 Biotech Stocks to Buy in March 2024 ↗
    Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors. 
    Via InvestorPlace
    News headline image
    Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
    Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
    Via MarketBeat
    News headline image
    Here's Why CRISPR Therapeutics Stock Climbed 34% in February ↗
    The biotech company keeps moving closer to bringing its promising first gene therapy to market. 
    Via The Motley Fool
    News headline image
    ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential ↗
    Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential. 
    Via InvestorPlace
    Topics Artificial Intelligence
    News headline image
    MarketBeat Week in Review – 2/26 - 3/1
    As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
    Via MarketBeat
    Topics Economy Stocks
    News headline image
    CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst ↗
    This company's fortunes are likely to improve, and soon. 
    Via The Motley Fool
    News headline image
    A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now ↗
    The futures for these two beaten-down stocks could be brighter than their recent pasts. 
    Via The Motley Fool
    News headline image
    Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗
    Both companies are working on treatments for genetic disorders. 
    Via Investor's Business Daily
    News headline image
    3 Biotech Stocks Bound to Blast Off By 2029 ↗
    Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years. 
    Via InvestorPlace
    News headline image
    bluebird bio: How to play LEAPS options for growth and income
    Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
    Via MarketBeat
    News headline image
    3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗
    Vertex shares have climbed almost 50% over the past year. 
    Via The Motley Fool
    News headline image
    Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗
    Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
    Via Benzinga
    News headline image
    3 Biotech Stocks to Buy and Hold for the Next 10 Years ↗
    There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
    Via The Motley Fool
    News headline image
    Is CRISPR Therapeutics the NVIDIA of gene editing?
    CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
    Via MarketBeat
    Topics Artificial Intelligence
    News headline image
    Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold ↗
    Buy this stock if you're daring, but avoid it for now if you aren't. 
    Via The Motley Fool
    News headline image
    Three S&P 500 Giants Lead This List Of Stocks Near Buy Points ↗
    Watch these five stocks, but the market is slightly extended. 
    Via Investor's Business Daily
    Topics Stocks
    News headline image
    Stock Market Rallies To Record High On Nvidia: Weekly Review ↗
    The stock market rally pulled back to start the week, but roared higher as booming Nvidia earnings and guidance fueled big AI-led gains. The S&P 500 and Dow Jones hit... Read More 
    Via Investor's Business Daily
    Topics Stocks
    News headline image
    Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    < Previous 1 2
    ...
    6 7 8 9 10 11 12 13 14
    ...
    35 36 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.